Literature DB >> 26766981

Primary extranodal NK/T-cell lymphoma of the lung: Mimicking bronchogenic carcinoma.

Chia-Hsin Liu1, Hong-Hau Wang2, Cherng-Lih Perng3, Chung-Kan Peng1, Chih-Feng Chian1, Chih-Hao Shen1.   

Abstract

Primary extranodal natural killer/T- cell lymphoma, nasal type (NK/TCL) in the lung is extremely rare and associated with Epstein-Barr virus (EBV) infection. An 80-year-old male presented with hemoptysis, which had lasted three days. Physical examination revealed inspiratory crackles at the left lung base and massive splenomegaly. Chest radiograph shows a mass-like lesion in the left lower lung but no active lesion six months earlier. Computed tomography demonstrated a soft tissue mass (size: 6.6 × 5.1 cm) with increased ground-glass opacities in the left lower lobe, several pulmonary nodules, and mediastinal lymphadenopathy. Transthoracic needle biopsy of the left-lower-lobe lung mass was performed. The pathology revealed atypical lymphoid cell infiltration, which is immunoreactive for cytoplasmic CD3, CD30 and CD56, but not reactive for CK and CD20. EBV-encoded RNA (EBER) was also detected in these atypical lymphoid cells. The serum EBV DNA level was 7.03 × 10(6) copies/mL and subtype 1 EBV was identified. No evidence of lymphoma involvement was found in the extrathoracic site. Primary pulmonary lymphoma showing nasal-type NK/T-cell subtype was diagnosed. Chemotherapy with cyclophosphamide and prednisolone was initiated immediately but the patient deteriorated and died three weeks later. In conclusion, patients presenting with rapidly growing lung mass and massive splenomegaly raise the possibility of aggressive pulmonary lymphoma. Extranodal NK/T-cell lymphoma with high baseline plasma EBV DNA levels signifies poor prognosis. Identifying young high-risk patients may have benefits for early aggressive and successful treatment.

Entities:  

Keywords:  Epstein-Barr virus; extranodal NK/T cell lymphoma; lung neoplasm; lymphoma

Year:  2014        PMID: 26766981      PMCID: PMC4704283          DOI: 10.1111/1759-7714.12021

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  17 in total

1.  Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity.

Authors:  G C Ooi; C S Chim; R Liang; K W Tsang; Y L Kwong
Journal:  AJR Am J Roentgenol       Date:  2000-04       Impact factor: 3.959

Review 2.  Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.

Authors:  J K Chan; V C Sin; K F Wong; C S Ng; W Y Tsang; C H Chan; M M Cheung; W H Lau
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

3.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Authors:  Arnaud Jaccard; Nathalie Gachard; Benoit Marin; Sylvie Rogez; Marie Audrain; Felipe Suarez; Hervé Tilly; Franck Morschhauser; Catherine Thieblemont; Loic Ysebaert; Alain Devidas; Barbara Petit; Laurence de Leval; Philippe Gaulard; Jean Feuillard; Dominique Bordessoule; Olivier Hermine
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

4.  Classification of natural killer (NK) cell and NK-like T-cell malignancies.

Authors:  E S Jaffe
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

5.  Rapid onset of pulmonary infiltration due to histiocytic lymphoma.

Authors:  N R Dunnick; B R Parker; R A Castellino
Journal:  Radiology       Date:  1976-02       Impact factor: 11.105

Review 6.  [Primary pulmonary involvement of NK/T-cell lymphoma: report of two cases with literature review].

Authors:  Yong-Long Xiao; De-Ping Zhang; Yihua Wang
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2007-12

Review 7.  NK/T cell lymphoma of the lung: a case report and review of literature.

Authors:  P Laohaburanakit; K A Hardin
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

Review 8.  Primary pulmonary lymphoma.

Authors:  J Cadranel; M Wislez; M Antoine
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

9.  Primary pulmonary lymphoma: relationship between clinical features and pathologic findings in 24 cases. The Japan National Chest Hospital Study Group for Lung Cancer.

Authors:  A Tamura; H Komatsu; N Yanai; J Homma; A Nagase; E Nemoto; T Hirai; T Hashizume; K Kawata; S Ishikawa
Journal:  Jpn J Clin Oncol       Date:  1995-08       Impact factor: 3.019

10.  Prolonged fever, hepatosplenomegaly, and pancytopenia in a 46-year-old woman.

Authors:  Liran Levy; Abedelmajeed Nasereddin; Moshe Rav-Acha; Meirav Kedmi; Deborah Rund; Moshe E Gatt
Journal:  PLoS Med       Date:  2009-04-14       Impact factor: 11.069

View more
  6 in total

1.  Primary pulmonary NK/T-cell lymphoma: A case report and literature review.

Authors:  Yajuan Qiu; Junna Hou; Dexun Hao; Dandan Zhang
Journal:  Mol Clin Oncol       Date:  2018-04-24

2.  [Clinical analyses of 24 patients with primary pulmonary NK/T-cell lymphoma].

Authors:  Y J Qiu; M Z Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

3.  A case of primary pulmonary NK/T cell lymphoma presenting as pneumonia.

Authors:  Sangho Lee; Bongkyung Shin; Hyungseok Yoon; Jung Yeon Lee; Gyu Rak Chon
Journal:  Respir Med Case Rep       Date:  2015-11-25

4.  Primary extranodal natural killer/T-cell lymphoma of bronchus and lung: A case report and review of literature.

Authors:  Chu-Chun Chien; Herng-Sheng Lee; Min-Hsi Lin; Pin-Pen Hsieh
Journal:  Thorac Cancer       Date:  2015-03-19       Impact factor: 3.500

Review 5.  Primary pulmonary extranodal NK/T-cell lymphoma of nasal type misdiagnosed as pneumonia: A case report and literature review.

Authors:  Juan Zhang; MaoJuan Wang; XiaoDong Yang; Chang Liu; Xin He
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  Late diagnosis: a case of rapidly progressive extranodal NK/T cell lymphoma, nasal type.

Authors:  Hiroyuki Mori; Kei Ebisawa; Mitsushige Nishimura; Kenji Kanazawa
Journal:  BMJ Case Rep       Date:  2018-02-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.